Finance

Beta
Lists
BOT:ASX
Botanix Pharmaceuticals Ltd
A$ ०.०२२
०.००%
(०.००) 1D
जुन ५, १६:१०:०३ GMT+१०  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for BOT...
Open
A$ ०.०२
High
A$ ०.०२
Low
A$ ०.०२
Mkt. cap
६.६२ करोड
Avg. vol.
१.९९ करोड
Volume
१.०९ करोड
52-wk high
A$ ०.३६
52-wk low
A$ ०.०२
EPS
-A$ ०.०५
Shares outstanding
२.७३ अरब
No. of employees
११
Open
A$ ०.०२
High
A$ ०.०२
Low
A$ ०.०२
Mkt. cap
६.६२ करोड
Avg. vol.
१.९९ करोड
Volume
१.०९ करोड
52-wk high
A$ ०.३६
52-wk low
A$ ०.०२
EPS
-A$ ०.०५
Shares outstanding
२.७३ अरब
No. of employees
११
Analyst outlook
Analyst Ratings
Based on 2 analysts giving stock ratings to BOT in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12 month forecast
Based on 2 Wall Street analysts offering 12 month price targets for BOT in the last 3 months.
Highest
Current A$ ०.०२
A$ १.०० (+४,४४५.४५%)
Average
A$ ०.५७ (+२,४९०.९१%)
Lowest
A$ ०.१४ (+५३६.३६%)
News stories
From sources across the web
Profile
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company's lead product is Sofdra, which treats axillary hyperhidrosis. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs. Wikipedia
About Botanix Pharmaceuticals Ltd
CEO-
Employees११
Founded१९८४
Headquarters-
Sector-
Websitebotanixpharma.com
Last report
२०२६ जनवरी २७
Fiscal period
Q2 2026
EPS / Est. (AUD)
- / -
Revenue / Est. (AUD)
८२.५३ लाख / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in AUD
२०२५ मार्च
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
Revenue
२७.०६ लाख
२७.०६ लाख
८२.५३ लाख
८२.५३ लाख
Cost of goods sold
१२.८१ लाख
१२.८१ लाख
२९.८० लाख
२९.८० लाख
Cost of revenue
१२.८१ लाख
१२.८१ लाख
२९.८० लाख
२९.८० लाख
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२.१४ करोड
२.१४ करोड
१.८३ करोड
१.८३ करोड
Operating expense
२.६९ करोड
२.६९ करोड
२.२१ करोड
२.२१ करोड
Total operating expenses
२.८२ करोड
२.८२ करोड
२.५१ करोड
२.५१ करोड
Operating income
-२.५५ करोड
-२.५५ करोड
-१.६८ करोड
-१.६८ करोड
Other non operating income
-
-
६.८३ लाख
६.८३ लाख
EBT including unusual items
-२.७८ करोड
-२.७८ करोड
-१.६६ करोड
-१.६६ करोड
EBT excluding unusual items
-२.७८ करोड
-२.७८ करोड
-१.६६ करोड
-१.६६ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-२.७८ करोड
-२.७८ करोड
-१.६६ करोड
-१.६६ करोड
Net profit margin
-१,०२५.७३%
-१,०२५.७३%
-२०१.११%
-२०१.११%
Earnings per share
-
-
-
-
Interest and investment income
३.४७ लाख
३.४७ लाख
३.५३ लाख
३.५३ लाख
Interest expense
-२६.६६ लाख
-२६.६६ लाख
-८.०२ लाख
-८.०२ लाख
Net interest expenses
-२३.१९ लाख
-२३.१९ लाख
-४.५० लाख
-४.५० लाख
Depreciation and amortization charges
५.७३ लाख
५.७३ लाख
५.९३ लाख
५.९३ लाख
EBITDA
-२.४९ करोड
-२.४९ करोड
-१.६२ करोड
-१.६२ करोड
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer